Zobrazeno 1 - 10
of 596
pro vyhledávání: '"Target antigen"'
Publikováno v:
Hemato, Vol 2, Iss 4, Pp 660-671 (2021)
Current data on CAR-T cell-based therapy is really promising in multiple myeloma, especially in terms of response. In heavily pretreated patients, who have already received proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies, curr
Externí odkaz:
https://doaj.org/article/d265ed9f333140bd87ceb70041da0f8b
Autor:
Christopher Schorr, Fabiana Perna
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Acute Myeloid Leukemia (AML) is an aggressive myeloid malignancy associated with high mortality rates (less than 30% 5-year survival). Despite advances in our understanding of the molecular mechanisms underpinning leukemogenesis, standard-of-care the
Externí odkaz:
https://doaj.org/article/29360531fc714cb1bd13c987c9a554ef
Autor:
Faroogh Marofi, Heshu Sulaiman Rahman, Zaid Mahdi Jaber Al-Obaidi, Abduladheem Turki Jalil, Walid Kamal Abdelbasset, Wanich Suksatan, Aleksei Evgenievich Dorofeev, Navid Shomali, Max Stanley Chartrand, Yashwant Pathak, Ali Hassanzadeh, Behzad Baradaran, Majid Ahmadi, Hossein Saeedi, Safa Tahmasebi, Mostafa Jarahian
Publikováno v:
Stem Cell Research & Therapy, Vol 12, Iss 1, Pp 1-23 (2021)
Abstract Acute myeloid leukemia (AML) is a serious, life-threatening, and hardly curable hematological malignancy that affects the myeloid cell progenies and challenges patients of all ages but mostly occurs in adults. Although several therapies are
Externí odkaz:
https://doaj.org/article/f28583801b814fceaa78f71fb9264eaf
Autor:
Yinyin Zhang, Yingmei Li, Weijie Cao, Fang Wang, Xinsheng Xie, Yadan Li, Xiaoyi Wang, Rong Guo, Zhongxing Jiang, Rongqun Guo
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Cellular immunotherapy represented by CD19-directed chimeric antigen receptor T (CAR-T) cells has achieved great success in recent years. An increasing number of CAR-T therapies are being developed for cancer treatment, but the frequent and varied ad
Externí odkaz:
https://doaj.org/article/a6f819bb5e5644008e7ec9c1215a347f
Autor:
Rita Assi, Huda Salman
Publikováno v:
Cells, Vol 11, Iss 24, p 3971 (2022)
Historical standard of care treatments of T-cell malignancies generally entailed the use of cytotoxic and depleting approaches. These strategies are, however, poorly validated and record dismal long-term outcomes. More recently, the introduction and
Externí odkaz:
https://doaj.org/article/dc2180fa15dd4891be76bf51f6eff5d4
Publikováno v:
Animals, Vol 12, Iss 16, p 2136 (2022)
In this study, we conducted a meta-analysis (MA) and systematic review to evaluate the effectiveness of vaccines against post-weaning diarrhea (PWD), caused by enterotoxigenic Escherichia coli (ETEC), in piglets. A Bayesian network meta-analysis (NMA
Externí odkaz:
https://doaj.org/article/60f997a1592e4489acecf94714a149f2
Publikováno v:
Cancers, Vol 14, Iss 6, p 1403 (2022)
Chimeric antigen receptors (CAR) T cells are T cells engineered to express membrane receptors with high specificity to recognize specific target antigens presented by cancer cells and are co-stimulated with intracellular signals to increase the T cel
Externí odkaz:
https://doaj.org/article/b9d6dfab8e9341229d7c1f01f86fe571
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lisa M Ebert, Wenbo Yu, Tessa Gargett, John Toubia, Paris M Kollis, Melinda N Tea, Brenton W Ebert, Cedric Bardy, Mark van den Hurk, Claudine S Bonder, Jim Manavis, Kathleen S Ensbey, Mariana Oksdath Mansilla, Kaitlin G Scheer, Sally L Perrin, Rebecca J Ormsby, Santosh Poonnoose, Barbara Koszyca, Stuart M Pitson, Bryan W Day, Guillermo A Gomez, Michael P Brown
Publikováno v:
Clinical & Translational Immunology, Vol 9, Iss 10, Pp n/a-n/a (2020)
Abstract Objectives Targeted immunotherapies such as chimeric antigen receptor (CAR)‐T cells are emerging as attractive treatment options for glioblastoma, but rely on identification of a suitable tumor antigen. We validated a new target antigen fo
Externí odkaz:
https://doaj.org/article/d95e2e808e74470a9794a5b6b9f9e770
Publikováno v:
Cancers, Vol 13, Iss 23, p 6136 (2021)
The incorporation of novel agents in recent treatments in multiple myeloma (MM) has improved the clinical outcome of patients. Specifically, the approval of monoclonal antibody (MoAb) against CD38 (daratumumab) and SLAMF7 (elotuzumab) in relapsed and
Externí odkaz:
https://doaj.org/article/4f118572cb5c4676ae741c73c7eb1bc7